CTI Plans Label Expansion For Zevalin After Acquiring The NHL Drug From Biogen
This article was originally published in The Pink Sheet Daily
Executive Summary
Cell Therapeutics intends to initiate clinical studies to expand use of the drug into front-line lymphoma settings.
You may also be interested in...
CTI Bags Cash, Turns Its Back On Zevalin
Buyer Spectrum downplays supplemental BLA delay in front-line non-Hodgkins lymphoma.
CTI Bags Cash, Turns Its Back On Zevalin
Buyer Spectrum downplays supplemental BLA delay in front-line non-Hodgkins lymphoma.
CTI Makes Over Zevalin As Front-Line NHL Therapy Booster
Drug is on FDA fast track and new partner is on board, but firm must still clear roadblocks to win acceptance in the marketplace.